Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EG5 | ISIN: US49721T5074 | Ticker-Symbol: 7EY
NASDAQ
04.06.25 | 21:47
3,200 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KIORA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
KIORA PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur KIORA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiKiora Pharmaceuticals berichtet über Ergebnisse der Jahreshauptversammlung-
DiKiora Pharmaceuticals inks potential $110 million deal with Senju3
DiKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia186Total potential deal value of $110 million plus royaltiesKiora to receive an immediate $1.25 million exclusive option feeIf the option is exercised, Kiora will receive an additional mid-single digit...
► Artikel lesen
KIORA PHARMACEUTICALS Aktie jetzt für 0€ handeln
DiKIORA PHARMACEUTICALS INC - 8-K, Current Report4
09.05.Kiora Pharmaceuticals GAAP EPS of -$0.522
09.05.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027328Encinitas, California--(Newsfile Corp. - May 9, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided an update...
► Artikel lesen
09.05.KIORA PHARMACEUTICALS INC - 8-K, Current Report2
09.05.KIORA PHARMACEUTICALS INC - 10-Q, Quarterly Report4
05.05.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy244Encinitas, California--(Newsfile Corp. - May 5, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the results from a preclinical study demonstrating KIO-104...
► Artikel lesen
04.04.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference319Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare...
► Artikel lesen
25.03.Kiora Pharmaceuticals GAAP EPS of $0.87 beats by $0.01, revenue of $16.02M misses by $0.75M4
25.03.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027250Encinitas, California--(Newsfile Corp. - March 25, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on...
► Artikel lesen
25.03.KIORA PHARMACEUTICALS INC - 8-K, Current Report5
25.03.KIORA PHARMACEUTICALS INC - S-8, Securities to be offered to employees in employee benefit plans2
25.03.KIORA PHARMACEUTICALS INC - 10-K, Annual Report2
12.03.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting254Encinitas, California--(Newsfile Corp. - March 12, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO-104 in a proliferative...
► Artikel lesen
13.02.Kiora Pharmaceuticals sichert sich neues Patent für KIO-1047
13.02.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104243Encinitas, California--(Newsfile Corp. - February 13, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matter...
► Artikel lesen
11.02.Kiora Pharmaceuticals, Inc.: Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema364Encinitas, California--(Newsfile Corp. - February 11, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLARITY...
► Artikel lesen
15.01.KIORA PHARMACEUTICALS INC - 8-K, Current Report1
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1